U.S. Generic Exclusivity Process To Go Public?
This article was originally published in PharmAsia News
The U.S. FDA wants to know whether its 180-day generic exclusivity process should be revealed up front; the question will be one of many on ANDA reviews to be considered at a September public hearing.
You may also be interested in...
CDER staff manual outlines seven categories of submissions that can qualify for expedited review, including some ANDAs with patent certifications and supplements that have the potential to create an “extraordinary hardship” for a sponsor if not addressed quickly.
Transition team leaders gain acting director titles, but “long and arduous” reorganization is not yet complete, CDER Director Woodcock notes.
Experts say one idea may be to borrow some new drug staff to help relieve the pressure; FDA says it will use all available resources.